TABLE 3.

Uni- and multivariate analyses of PFS and OS.

	PFS				OS
	Univariate		Multivariate		Univariate		Multivariate
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Sex (male vs. female)	0.845 (0.536–1.332)	0.469	–	–	0.532 (0.290–0.987)	0.042	0.392 (0.210-0.731)	0.003
Age (≤65 vs. >65 years)	1.114 (0.650–1.910)	0.659	–	–	1.649 (0.763–3.566)	0.204	–	–
Treatment line (first vs. >first)	1.939 (1.228–3.064)	0.005	1.639 (1.018–2.639)	0.042	2.109 (1.146–3.882)	0.016	–	–
BMI (< 18.5 vs. ≥18.5)	0.246 (0.129–0.471)	0.001	2.074 (1.043–4.127)	0.025	0.159 (0.780–0.326)	(0.001	0.176 (0.082–0.377)	<0.001
MLR (<0.31 vs. ≥0.31)	2.405 (1.506–3.839)	0.001	1.813 (1.076–3.055)	0.025	2.630 (1.437–4.814)	0.001	2.184 (1.140–4.183)	0.018
PLR (<135 vs. ≥135)	1.184 (1.196–2.968)	0.006	–	–	1.768 (0.966–3.235)	0.065	–	–
NLR (< 5.0 vs. 5.0)	3.425 (1.951–6.014)	(0.001	1.887 (0.968–3.677)	0.062	2.343 (1.155–4.753)	0.015	–	–
Liver metastasis (no vs. yes)	1.648 (1.047–2.595)	0.031	–	–	1.525 (0.850–2.739)	0.154	–	–
Chemotherapy (yes vs. no)	1.529 (0.959–2.438)	0.074	–	–	1.233 (0.662–2.296)	0.509	–	–
Targeted therapy (yes vs. no)	1.343 (0.847–2.132)	0.210	–	–	1.091 (0.602–1.978)	0.774	–	–
Radiotherapy (yes vs. no)	1.044 (0.421-2.588)	0.926	–	–	1.232 (0.381-3.989)	0.727	–	–

P values in bold indicate statistically significant differences (P < 0.05).

BMI, body mass index; CI, confidence interval; HR, hazard ratio; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.